ATP7B

ATP7B

Introduction

```mermaid
flowchart TD
classDef gene fill:#0a1f0a,stroke:#4caf50
classDef protein fill:#0a1929,stroke:#2196f3
classDef disease fill:#2d0f0f,stroke:#e91e63
classDef pathway fill:#3e2200,stroke:#ff9800
classDef mechanism fill:#1a0a1f,stroke:#9c27b0
classDef therapeutic fill:#e0f2f1,stroke:#009688
ATP7B["ATP7B"] -->|"implicated_in"| neurodegeneration["neurodegeneration"]
ATP7B["ATP7B"] -->|"implicated_in"| ALZHEIMER["ALZHEIMER"]
ATP7B["ATP7B"] -->|"implicated_in"| AMYLOID["AMYLOID"]
ATP7B["ATP7B"] -->|"implicated_in"| ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
ATP7B["ATP7B"] -->|"implicated_in"| APP["APP"]
ATP7B["ATP7B"] -->|"implicated_in"| SOD1["SOD1"]
ATP7B["ATP7B"] -->|"implicated_in"| AMYOTROPHIC_LATERAL_SCLEROSIS["AMYOTROPHIC LATERAL SCLEROSIS"]
ATP7B["ATP7B"] -->|"implicated_in"| Cirrhosis["Cirrhosis"]
ATP7B["ATP7B"] -->|"implicated_in"| Ataxia["Ataxia"]
ATP7B["ATP7B"] -->|"implicated_in"| Amyotrophic_Lateral_Sclerosis["Amyotrophic Lateral Sclerosis"]
ATP7B["ATP7B"] -->|"implicated_in"| Aging["Aging"]
ATP7B["ATP7B"] -->|"implicated_in"| Parkinson["Parkinson"]
ATP7B["ATP7B"] -->|"implicated_in"| Als["Als"]
ATP7B["ATP7B"] -->|"implicated_in"| Alzheimer["Alzheimer"]
ATP7B["ATP7B"] -->|"implicated_in"| Neurodegeneration["Neurodegeneration"]
ATP7B["ATP7B"] -->|"implicated_in"| Oxidative_Stress["Oxidative Stress"]
ATP7B["ATP7B"] -->|"implicated_in"| Chaperone["Chaperone"]
CP["CP"] -->|"interacts_with"| ATP7B["ATP7B"]
NEURODEGENERATION["NEURODEGENERATIO

ATP7B

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ATP7B</th>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">H1069Q</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">R778L</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">A874V</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">2299insC</td>
<td>Frameshift</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Wilson Disease</td>
</tr>
<tr>
<td class="label">Tremor</td>
<td>Wing-beating tremor</td>
</tr>
<tr>
<td class="label">Dystonia</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Kayser-Fleischer rings</td>
<td>Present in 90%</td>
</tr>
<tr>
<td class="label">Ceruloplasmin</td>
<td>Low</td>
</tr>
<tr>
<td class="label">MRI findings</td>
<td>Basal ganglia lesions</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">20 edges</a></td>
</tr>
</table>

Atp7B Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

ATP7B is a copper-transporting P-type ATPase gene that plays a central role in systemic copper homeostasis and is the primary disease gene in [Wilson's Disease](/diseases/wilsons).[@easlern2025][@czonkowska2018] ATP7B is highly expressed in hepatocytes, where it [@czonkowska2018]
supports both copper incorporation into ceruloplasmin and biliary copper excretion. Pathogenic ATP7B variants reduce these functions and drive progressive copper overload with [@alkhouri2023]
hepatic and neurologic toxicity.[@easlern2025][@alkhouri2023] [@bull1993]

Gene and Protein Structure

Chromosomal Location and Gene Organization

The ATP7B gene is located on chromosome 13q14.3 and consists of 21 exons spanning approximately 80 kb of genomic DNA. The gene encodes a transmembrane protein of 1465 amino acids with a molecular weight of approximately 165 kDa. [@djebranioussedik2025]

Protein Domains

ATP7B belongs to the P-type ATPase family (E1-E2 ATPases) and contains several critical functional domains: [@jing2024]

• N-terminal metal-binding domain: Contains six copper-binding motifs (CXXC) that sense intracellular copper levels
• Phosphorylation domain (P-domain): Contains the conserved DKTGTLT motif essential for ATP hydrolysis
• ATP-binding domain (A-domain): Responsible for ATP binding and energy transduction
• Transmembrane domain: Forms the channel for copper ion translocation across the membrane
• Actuator domain (A-domain): Involved in conformational changes during the transport cycle

Expression Pattern

ATP7B is predominantly expressed in: [@su2024]

• Hepatocytes (liver) - highest expression
• Brain (choroid plexus, astrocytes)
• Kidney
• Placenta
• Small intestine

Protein Function and Copper Homeostasis

Copper Transport Mechanism

ATP7B operates through a sophisticated conformational cycle characteristic of P-type ATPases: [@padula2022]

Key Functions

Under physiologic copper conditions, ATP7B performs two essential functions: [@murillo2016]

• Ceruloplasmin biosynthesis: ATP7B loads six copper atoms onto apoceruloplasmin in the trans-Golgi network, producing functional ceruloplasmin (holo-ceruloplasmin) which is secreted into the bloodstream[@easlern2025]
• Biliary copper excretion: With rising intracellular copper, ATP7B traffics toward vesicular/canalicular compartments to facilitate copper export into bile for elimination[@czonkowska2018]

Copper Chaperone Network

Cellular copper homeostasis requires specialized chaperone proteins: [@murillo2022]

• CTR1: Copper importer on the cell membrane
• CCS (Copper Chaperone for SOD1): Delivers copper to SOD1
• COX17: Delivers copper to cytochrome c oxidase
• ATOX1: Antisense oxidoreductase 1 - delivers copper to ATP7B/ATP7A

Role in Neurodegeneration

Although ATP7B is classically considered a hepatology gene, its dysfunction has major neurologic consequences via systemic copper dysregulation. Copper spillover from hepatic
failure to maintain homeostasis contributes to deposition and injury in motor and cognitive circuits, especially in the [basal ganglia](/brain-regions/basal-ganglia).<a
href="#references" class="ref-link" data-ref-number="2" data-ref-text="Członkowska A et al., Wilson disease (2018)" title="Członkowska A et al., Wilson disease
(2018)"> class="ref-link" data-ref-number="2" data-ref-text="Członkowska A et al., Wilson disease (2018)" title="Członkowska A et al., Wilson disease (2018)">2</a></a>[@jing2024][@su2024]

Neurologic Manifestations

Copper accumulation in the brain leads to:

• Movement disorders: Tremor, dystonia, parkinsonism
• Neuropsychiatric symptoms: Depression, anxiety, personality changes
• Cerebellar involvement: Ataxia, dysarthria
• Cognitive impairment: Progressive dementia in advanced cases

Brain Regions Affected

The basal ganglia are particularly vulnerable, especially:

• Putamen: Most commonly affected
• Globus pallidus
• Thalamus
• Brainstem nuclei

Disease-Associated Variants

Common Pathogenic Variants

Hundreds of ATP7B pathogenic variants have been reported worldwide, with substantial geographic heterogeneity:

Genotype-Phenotype Correlations

• Null/null genotypes: Often present with severe hepatic disease
• Residual function variants: May present with primarily neurologic manifestations
• Compound heterozygotes: Variable phenotype depending on allele combination

Diagnostics and Biomarkers

Molecular Testing

ATP7B molecular testing is now part of standard workups for suspected Wilson disease when biochemical findings are inconclusive or family screening is needed.[@easlern2025][@alkhouri2023]

Biochemical Markers

• Serum ceruloplasmin: Typically low (<20 mg/dL)
• 24-hour urinary copper excretion: Elevated (>100 μg/24h)
• Serum copper: Variable; non-ceruloplasmin-bound "free" copper elevated
• Relative exchangeable copper (REC): New biomarker with high specificity[@djebranioussedik2025]

Neuroimaging

MRI findings in neurologic Wilson disease include:[@jing2024][@su2024]

• T2 hyperintensities in basal ganglia
• Central pontine myelinolysis-like changes
• Cerebral atrophy (advanced cases)
• Copper deposition visible on susceptibility-weighted imaging (7T MRI)

Therapeutic Targeting

Current Management

Current disease management still relies on:

• Copper chelation: Penicillamine, trientine
• Zinc salts: Block intestinal copper absorption
• Dietary copper restriction
• Liver transplantation: For acute liver failure or end-stage disease

Emerging Disease-Modifying Approaches

ATP7B is also a direct target for emerging disease-modifying approaches:

• AAV-linked ATP7B gene replacement: Preclinical studies show durable correction of copper metabolism in murine models[@murillo2016]
• Protein trans-splicing: Full-length ATP7B reconstitution through protein trans-splicing corrects Wilson disease in mice[@padula2022]
• Small molecule correctors: Pharmacologic enhancement of residual ATP7B function
• Copper chaperone modulation: Targeting ATOX1 or CCS to reduce toxic copper accumulation

Gene Therapy Progress

Preclinical studies in murine models have demonstrated:

• Durable correction of copper metabolism after ATP7B restoration[@murillo2016]
• 64Cu PET imaging can evaluate restoration of physiological copper excretion pathways[@murillo2022]
• Successful rescue of hepatic copper accumulation
• Prevention of neurologic complications when treated early

See Also

• [Wilson's Disease](/diseases/wilsons)
• [Wilson's Disease](/diseases/wilsons-disease)
• [Aceruloplasminemia](/diseases/aceruloplasminemia)
• [Menkes Disease](/diseases/menkes-disease) - related copper transport disorder
• [Genetics of Neurodegenerative Diseases](/mechanisms/genetics)
• [Metal Homeostasis](/mechanisms/metal-homeostasis-dysregulation)
• [Basal Ganglia](/brain-regions/basal-ganglia)

External Links

• [NCBI Gene: ATP7B](https://www.ncbi.nlm.nih.gov/gene/540)
• [OMIM: Wilson Disease / ATP7B](https://omim.org/entry/606882)
• [Uniprot: ATP7B (P35602)](https://www.uniprot.org/uniprot/P35602)

Brain Atlas Resources

• [Allen Human Brain Atlas*: [ATP7B Gene expression search](https://human.brain-map.org/microarray/search/show?search_term=ATP7B+Gene)](/datasets/allen-human-brain-atlas)
• [Allen Mouse Brain Atlas*: [ATP7B Gene search](https://mouse.brain-map.org/search/index.html?query=ATP7B+Gene)](/projects/brain-atlas)
• [Allen Cell Type Atlas*: [Transcriptomic cell type reference](https://portal.brain-map.org](/cell-types/atlas)/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [ATP7B Gene developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=ATP7B+Gene)

Background

The study of Atp7B Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Molecular Mechanism of Copper Transport

P-Type ATPase Catalytic Cycle

ATP7B is a member of the P-type ATPase family, one of the largest and most important families of membrane transport proteins. These enzymes use the energy from ATP hydrolysis to transport ions across membranes, and their mechanism is highly conserved across species.

The E1-E2 Conformational Cycle:

This cycle allows ATP7B to transport copper against steep concentration gradients using energy from ATP hydrolysis.

N-Terminal Metal-Binding Domains

The N-terminal region of ATP7B contains six copper-binding domains (MBD1-MBD6):

• MBD1-MBD3: Critical for copper sensing and regulatory functions
• MBD4-MBD6: Important for copper transfer to the transport site

Copper Chaperone ATOX1

ATOX1 (Antisense Oxidoreductase 1) is the copper chaperone that delivers copper to ATP7B:

• Structure: A small 68 amino acid protein with a copper-binding CXXC motif
• Function: Transfers copper from cytosolic pools to ATP7B in the trans-Golgi network
• Interaction: ATOX1 directly interacts with the N-terminal MBDs of ATP7B
• Therapeutic target: Modulating ATOX1 could affect copper delivery to ATP7B

ATP7B and Neurodegeneration

Copper Toxicity Mechanisms

In Wilson disease, copper accumulation in the brain leads to neurodegeneration through multiple mechanisms:

Oxidative stress:

• Copper catalyzes the production of reactive oxygen species (ROS) through Fenton chemistry
• Enhanced lipid peroxidation in basal ganglia
• Damage to mitochondrial function
• Impaired antioxidant defenses

• Copper can promote protein misfolding and aggregation
• Interference with normal protein degradation pathways
• Synergistic effects with other neurodegenerative processes

• Copper modulates glutamate receptor function
• May enhance excitotoxic cell death
• Particularly relevant in the basal ganglia

Neuroimaging Patterns

Advanced MRI techniques reveal characteristic patterns in Wilson disease:

T2-weighted MRI:

• Hyperintensities in putamen (most common)
• Globus pallidus involvement
• Thalamic lesions
• Brainstem involvement (central pontine myelinolysis-like)
• Cerebellar atrophy in chronic cases

• Copper deposition visible as hypointense regions
• 7T MRI can resolve specific patterns
• Useful for tracking treatment response

• White matter tract disruption
• Fractional anisotropy changes precede structural lesions
• Correlates with clinical disability

Comparison with Parkinson's Disease

Wilson disease can present with parkinsonian features, leading to diagnostic confusion:

This overlap underscores the importance of considering copper metabolism in basal ganglia disorders.

ATP7B in Other Neurodegenerative Conditions

Alzheimer's Disease

Copper homeostasis is altered in Alzheimer's disease:

• Elevated brain copper in AD patients
• Copper interacts with amyloid-beta plaques
• ATP7B expression changes in AD brain
• Copper chelation trials in AD have shown mixed results

Other Copper-Related Disorders

Aceruloplasminemia:

• Caused by mutations in CP (ceruloplasmin) gene
• Similar neurologic manifestations to Wilson disease
• Iron and copper metabolism both affected
• Neurodegeneration in basal ganglia

• Caused by ATP7A mutations
• X-linked recessive disorder
• Severe neurodegeneration in infancy
• Distinct from Wilson disease in presentation

Treatment Approaches

Copper Chelation Therapy

Penicillamine:

• Classic first-line treatment
• Mobilizes copper from tissue stores
• Can worsen neurologic symptoms initially
• Requires long-term treatment

• Alternative chelator with better side effect profile
• Less likely to worsen neurologic symptoms
• First-line in many current protocols

• Newer chelator with potential advantages
• Triangular molecule that binds copper tightly
• May protect against copper-induced toxicity better

Zinc Therapy

Zinc salts block intestinal copper absorption:

• Competes with copper for absorption
• Induces metallothionein in enterocytes
• Useful for maintenance therapy
• May be sufficient for some patients

Liver Transplantation

Indications for transplantation:

• Acute liver failure
• Decompensated cirrhosis unresponsive to medical therapy
• Some cases with severe neurologic symptoms
• Improves copper metabolism systemically

Gene Therapy and Emerging Approaches

AAV-Mediated Gene Transfer

Preclinical studies have shown promise:

• AAV vectors efficiently deliver ATP7B to hepatocytes
• Long-term expression achieved
• Correction of copper metabolism in animal models
• 64Cu PET used to verify physiologic function
• Clinical trials in development

Protein-Based Therapies

Protein trans-splicing:

• Full-length ATP7B reconstitution
• Uses split-intein technology
• Corrects disease in mouse models
• Could be applicable to patients with null alleles

Pharmacologic Approaches

Small molecule correctors:

• Target misfolded ATP7B variants
• Enhance residual function
• Could benefit patients with missense variants

• Target ATOX1 to reduce copper delivery
• Reduce copper-mediated toxicity
• Complementary to other approaches

Diagnostic Challenges and Biomarkers

Relative Exchangeable Copper (REC)

A newer biomarker with high specificity:

• Measures exchangeable copper fraction
• Higher sensitivity than traditional tests
• Useful for diagnosis and monitoring
• REC > 15% suggests Wilson disease

Genetic Testing

ATP7B sequencing is now widely available:

• Identifies pathogenic variants
• Enables family screening
• Guides prognosis (residual function)
• Preimplantation genetic diagnosis possible

Challenges in Diagnosis

• Overlapping features with other disorders
• Variable penetrance of variants
• Incomplete genotype-phenotype correlation
• Need for integration of multiple tests

Research Directions

Current Research Areas

Unresolved Questions

• Why do some patients develop severe neurologic disease?
• Can early treatment prevent neurodegeneration?
• What determines treatment response?
• Is there a role for combination therapies?

See Also

• [Wilson's Disease](/diseases/wilsons)
• [Wilson's Disease](/diseases/wilsons-disease)
• [Aceruloplasminemia](/diseases/aceruloplasminemia)
• [Menkes Disease](/diseases/menkes-disease)
• [Genetics of Neurodegenerative Diseases](/mechanisms/genetics)
• [Metal Homeostasis](/mechanisms/metal-homeostasis-dysregulation)
• [Basal Ganglia](/brain-regions/basal-ganglia)
• [Copper Metabolism](/mechanisms/copper-metabolism)
• [Oxidative Stress](/mechanisms/oxidative-stress)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving ATP7B discovered through SciDEX knowledge graph analysis: